Table 2.

Baseline characteristics in two study groups

Category		Intervention group (N = 16)	Control group (N = 19)
Gender	Female	15 (93.8%)	17 (89.5%)
	Male	1 (6.2%)	2 (10.5%)
Age (years)- Mean (standard deviation)		37.1 (9.7)	37.3 (9.2)
Migraine duration (years)- Mean (standard deviation)		16.2 (10.9)	9.3 (8.1)
Education	High school diploma	7 (43.8%)	8 (42.1%)
	Bachelor’s degree	5 (31.3%)	7 (36.8%)
	Master’s degree	3 (18.8%)	3 (15.8%)
	PhD or equivalent	1 (6.3%)	1 (5.3%)
Job	Unemployed/ Housewife	10 (62.5%)	8 (44.4%)
	Student	1 (6.3%)	2 (11.1%)
	Teacher	1 (6.3%)	2 (11.1%)
	University professor	1 (6.3%)	1 (5.6%)
	Accountant	1 (6.3%)	0
	Manager	1 (6.3%)	0
	Self-employed	0	2 (11.1%)
	Other	1 (6.3%)	3 (16.7%)
	Prefer not to say	0	1 (5.6%)
Migraine medications	Sodium valproate, 200 mg or 400 mg daily	13 (81.3%)	18 (94.7%)
	Maprotiline, 20 mg daily	7 (43.8%)	5 (26.3%)
	Verapamil, 20 mg daily	4 (25%)	7 (36.8%)
	Propranolol, 20 or 40 mg daily	4 (25%)	10 (52.6%)
	Sertraline, 50 mg daily	2 (12.5%)	4 (21.1%)
	Nortriptyline, 20 mg daily	1 (6.3%)	0
	Topiramate, 200 mg daily	1 (6.3%)	0
	Doxepin, 10 mg daily	1 (6.3%)	0
	Metoprolol, 40 mg daily	1 (6.3%)	1 (5.3%)
	Amitriptyline, 20 mg	0	1 (5.3%)
	Citalopram, 20 mg	0	1 (5.3%)
Other diseases	Gastroesophageal reflux disease	1 (6.3%)	0
	Hyperlipidemia	1 (6.3%)	1 (5.3%)
	Hypothyroidism	0	1 (5.3%)
	Inflammatory bowel disease	1 (6.3%)	0
	Mild asthma	0	1 (5.3%)
	Multiple sclerosis	1 (6.3%)	0
Mostly used pain relievers	Acetaminophen	0	1 (5.3%)
	Diclofenac (supp)	1 (6.3%)	2 (10.5%)
	Ibuprofen (tab)	6 (37.5%)	9 (47.4%)
	Ibuprofen (cap)	0	6 (31.6%)
	Mixed pain relievers (acetaminophen, ibuprofen, caffeine)	9 (56.3%)	0